INmune Bio Future Growth

NasdaqCM:INMB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	0	-40	N/A	N/A	2
12/31/2025	0	-39	N/A	N/A	2
12/31/2024	0	-41	N/A	N/A	3
12/31/2023	0	-30	-12	-12	N/A
9/30/2023	0	-27	-14	-14	N/A
6/30/2023	0	-27	-13	-13	N/A
3/31/2023	0	-27	-15	-15	N/A
12/31/2022	0	-27	-23	-23	N/A
9/30/2022	0	-31	-27	-27	N/A
6/30/2022	0	-33	-31	-31	N/A
3/31/2022	0	-33	-32	-32	N/A
12/31/2021	0	-30	-29	-29	N/A
9/30/2021	0	-24	-21	-21	N/A
6/30/2021	0	-19	-17	-17	N/A
3/31/2021	0	-15	-13	-13	N/A
12/31/2020	0	-12	-9	-9	N/A
9/30/2020	N/A	-11	-7	-7	N/A
6/30/2020	N/A	-10	-5	-5	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-8	-5	-5	N/A
9/30/2019	N/A	-7	-5	-5	N/A
6/30/2019	N/A	-6	-4	-4	N/A
3/31/2019	N/A	-11	-3	-3	N/A
12/31/2018	N/A	-12	-2	-2	N/A
9/30/2018	N/A	-11	-2	-2	N/A
6/30/2018	N/A	-10	-2	-2	N/A
3/31/2018	N/A	-4	-1	-1	N/A
12/31/2017	N/A	-1	-1	-1	N/A
9/30/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INMB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INMB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INMB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INMB's revenue (68.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: INMB's revenue (68.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INMB's Return on Equity is forecast to be high in 3 years time

INmune Bio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates decrease by 35%, EPS upgraded

Consensus revenue estimates increase by 30%, EPS downgraded

Consensus revenue estimates increase by 51%

Price target decreased to US$14.33

Consensus revenue estimates increase by 24%

Price target decreased to US$22.33

Recent updates

INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million.

Independent Director recently bought US$246k worth of stock

Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024

INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program

New minor risk - Share price stability

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA

Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Consensus revenue estimates increase by 30%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line

INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference

INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Consensus revenue estimates increase by 51%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer

Insufficient new directors

INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Price target decreased to US$14.33

Inmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of Xpro1595 in Mild Alzheimer’S Disease

Consensus revenue estimates increase by 24%

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.55 loss in 3Q 2021)

INmune Bio, Inc. to Report Q3, 2022 Results on Nov 02, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.44 loss in 2Q 2021)

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

CFO, Treasurer & Secretary recently bought US$69k worth of stock

INmune Bio: Possibly The Once In A Lifetime Dip

INmune Bio, Inc. Provides Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease

Inmune Bio, Inc. Presents Data Demonstrating Xpro™ Promotes Remyelination in Gray Matter At 3rd European Conference on Neuroinflammation

Price target decreased to US$22.33

INmune Bio, Inc., Annual General Meeting, Jun 01, 2022

INmune Bio, Inc. Announces Dosing of First Patient Enrolled in its Phase 2 Trial Using XPro1595 (XPro™) to Treat Neuroinflammation as Cause of Alzheimer’s Disease

INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research Annual Meeting 2022

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target decreased to US$24.33

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

Price target increased to US$35.00

INmune Bio A No-Brainer Investment

Co-Founder exercised options to buy US$601k worth of stock.

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming Pseudokine, INKmune

INmune Bio: High-Risk High-Reward Alzheimer's Play

Our Bullish Take On INmune Bio's Drug Pipeline

Consensus forecasts updated